Skip to main content
CVE-2025-61940VulnerabilityPublished Updated

CVE-2025-61940: Mirion Medical EC2 Software NMIS BioDose · CWE-603

Affects Mirion Medical EC2 Software NMIS BioDoseSource CVE Database V5

0

Not known to be exploited · CVSS 8.7 High.

Data as of 25 Oct 2026, 19:02 UTC

CVSS 4.0 base score
8.7High
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.3% chance of exploitation in 30 days – higher than 25% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 2026-10-25.

What to do

Affected software

ProductAffectedFixed in
Mirion Medical EC2 Software NMIS BioDoseAffected
  • =0
Fixed in–

AI-suggested

European organizations should prioritize upgrading to the latest NMIS/BioDose version that supports Windows user authentication to enforce per-user database access controls. Until upgrades are applied, restrict network access to the SQL Server instance hosting the NMIS/BioDose database using firewalls and network segmentation to limit exposure. Implement strict access controls on client machines running the software, including endpoint protection and least privilege principles to reduce the risk of local compromise. Monitor database access logs for unusual activity indicative of unauthorized access attempts. Consider deploying database activity monitoring tools to detect and alert on anomalous queries or connections. Conduct regular audits of user accounts and credentials used by the software to ensure no unauthorized sharing or leakage. Engage with Mirion Medical support for any available patches or workarounds and maintain awareness of emerging exploit reports. Finally, integrate this vulnerability into incident response plans to enable rapid containment if exploitation is suspected.

Description

NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.

References

Community reviews

Loading reviews…